https://www.selleckchem.com/pr....oducts/muvalaplin.ht
ong immunocompromised children may be a protective factor against a severe COVID-19. To evaluate the outcomes of a 6-month follow-up after switching to brolucizumab from aflibercept to treat neovascular age-related macular degeneration (AMD) in Japanese patients. Retrospective observational study. We studied 45 consecutive eyes of 42 patients diagnosed with neovascular AMD, who were switched to intravitreal brolucizumab injection (IVBr) after receiving intravitreal aflibercept injection (IVA) using a treat-and-extend (TAE) regimen. P
Like
Comment
Share
